Ascendis Bone Drug Patent Portfolio
Ascendis Bone owns 1 orange book drug protected by 9 US patents Given below is the list of Ascendis Bone's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403182 | Liquid Pharmaceutical Formulations Of Pth Conjugates | 12 Nov, 2042 | Active |
| US11590207 | Dosage regimen for a controlled-release PTH compound | 28 Sep, 2037 | Active |
| US11759504 | PTH compounds with low peak-to-trough ratios | 28 Sep, 2037 | Active |
| US11857603 | PTH compounds with low peak-to-trough ratios | 28 Sep, 2037 | Active |
| US11890326 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US11918628 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US12295989 | Controlled-release PTH compound | 28 Sep, 2037 | Active |
| US12453778 | Incremental Dose Finding In Controlled-Release Pth Compounds | 28 Sep, 2037 | Active |
| US8906847 | Prodrug comprising a drug linker conjugate | 30 Apr, 2031 | Active |
Latest Legal Activities on Ascendis Bone's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ascendis Bone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent eCertificate of Correction | 09 Sep, 2025 | US12295989 |
| Mail Patent eCofC Notification | 09 Sep, 2025 | US12295989 |
| Recordation of Patent Grant Mailed | 09 Sep, 2025 | US12403182 |
| Email Notification | 09 Sep, 2025 | US12295989 |
| Patent eCofC Notification | 09 Sep, 2025 | US12295989 |
| Patent eGrant Notification | 02 Sep, 2025 | US12403182 |
| Recordation of Patent eGrant | 02 Sep, 2025 | US12403182 |
| Email Notification | 02 Sep, 2025 | US12403182 |
| Mail Patent eGrant Notification | 02 Sep, 2025 | US12403182 |
| Patent Issue Date Used in PTA Calculation | 02 Sep, 2025 | US12403182 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US11857603 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US11918628 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US11890326 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US11890326 |
| Email Notification | 21 Aug, 2025 | US12403182 |
Ascendis Bone's Family Patents
Ascendis Bone Drug List
Given below is the complete list of Ascendis Bone's drugs and the patents protecting them.
1. Yorvipath
Yorvipath is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403182 | Liquid Pharmaceutical Formulations Of Pth Conjugates |
12 Nov, 2042
(16 years from now)
| Active |
| US11590207 | Dosage regimen for a controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US11759504 | PTH compounds with low peak-to-trough ratios |
28 Sep, 2037
(11 years from now)
| Active |
| US11857603 | PTH compounds with low peak-to-trough ratios |
28 Sep, 2037
(11 years from now)
| Active |
| US11890326 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US11918628 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US12295989 | Controlled-release PTH compound |
28 Sep, 2037
(11 years from now)
| Active |
| US12453778 | Incremental Dose Finding In Controlled-Release Pth Compounds |
28 Sep, 2037
(11 years from now)
| Active |
| US8906847 | Prodrug comprising a drug linker conjugate |
30 Apr, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yorvipath's drug page